For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221012:nRSL5590Ca&default-theme=true
RNS Number : 5590C Oxford Biomedica PLC 12 October 2022
PDMR Dealings
Oxford, UK - 12 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the
Company") (LSE:OXB), was informed on 11 October 2022, that Tim Kelly, Chief
Executive Officer of Oxford Biomedica Solutions, exercised 14,690 RSU (2022)
options at nil cost on 10 October 2022, and sold all the resulting ordinary
shares at 315p per share on 11 October 2022. Following this transaction, Tim
Kelly continues to hold 176,615 options over ordinary shares.
The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of ordinary shares
exercised and then sold.
1. Details of the Person Discharging Managerial Responsibility ("PDMR")
a) Name Tim Kelly
2. Reason for the notification
a) Position/status Chief Executive Officer of Oxford Biomedica Solutions
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Options over ordinary shares of 50 pence each
Identification code
ISIN: GB00BDFBVT43
b) Nature of the transaction Exercise of options
c) Currency GBP - British pound
d) Price(s) and volumes(s)
Price(s) Volume(s)
Nil 14,690
e) Aggregated information
- Aggregate volume 14,690
- Aggregated total
Nil
f) Date of the transaction 2022-10-10
g) Place of the transaction Outside a trading venue
e)
Aggregated information
- Aggregate volume
- Aggregated total
14,690
Nil
f)
Date of the transaction
2022-10-10
g)
Place of the transaction
Outside a trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")
a) Name Tim Kelly
2. Reason for the notification
a) Position/status Chief Executive Officer of Oxford Biomedica Solutions
b) Initial notification/ Initial Notification
amendment
3. Details of the Issuer
a) Name Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument Ordinary Shares of 50 pence each
Identification code
ISIN: GB00BDFBVT43
b) Nature of the transaction Sale of ordinary shares
c) Currency GBP - British pound
d) Price(s) and volumes(s)
Price(s) Volume(s)
£3.15 14,690
e) Aggregated information
- Aggregate volume 14,690
- Aggregated total
£46,273.50
f) Date of the transaction 2022-10-11
g) Place of the transaction London Stock Exchange, Main Market (XLON)
e)
Aggregated information
- Aggregate volume
- Aggregated total
14,690
£46,273.50
f)
Date of the transaction
2022-10-11
g)
Place of the transaction
London Stock Exchange, Main Market (XLON)
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.
Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
US based subsidiary AAV manufacturing and innovation business, based near
Boston, US.
Further information is available at www.oxb.com (http://www.oxb.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFFUESFEESEFS